Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies will terminate its Phase 3 LOTUS study evaluating Stelara (ustekinumab) in patients with an autoimmune disorder called systemic lupus erythematosus.
The company decided to pull the plug after a pre-planned analysis of preliminary data failed to show enough of a treatment effect.
It says its decision will not affect any other ongoing studies or current indications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.